Get the Stockscreener App
18.24
0.06%
0.0899
Amneal Pharmaceuticals Inc stock is traded at $18.24, with a volume of 1.01M.
It is up +0.06% in the last 24 hours and up +1.74% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$18.15
Open:
$18.01
24h Volume:
1.01M
Relative Volume:
0.51
Market Cap:
$6.35B
Revenue:
$3.05B
Net Income/Loss:
$181.32M
P/E Ratio:
48.90
EPS:
0.373
Net Cash Flow:
$186.11M
1W Performance:
+1.57%
1M Performance:
+1.74%
6M Performance:
+19.55%
1Y Performance:
+92.17%
1-Day Range:
$17.92
$18.37
1-Week Range:
$16.77
$18.37
52-Week Range:
$9.20
$19.26
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
18.23 | 6.32B | 3.05B | 181.32M | 186.11M | 0.373 |
TAK
Takeda Pharmaceutical Co Adr
|
17.38 | 56.30B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.46 | 42.85B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.595 | 42.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.67 | 30.49B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
505.97 | 21.43B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | UBS | Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026 - Kalkine Media
A Look at Amneal Pharmaceuticals Inc (AMRX) After 5.1% Gain -- G - GuruFocus
Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) Director Sells $882,000.00 in Stock - MarketBeat
Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity - Stock Titan
Sell Alert: Nikita Shah Cashes Out $2.56M In Amneal Pharmaceuticals Stock - Benzinga
Amneal Pharmaceuticals(AMRX.US) Officer Sells US$3.77 Million in Common Stock - Moomoo
Nikita Shah Sells 146,403 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock - MarketBeat
Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 6,613 Shares - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 210,000 Shares of Stock - MarketBeat
Amneal Pharmaceuticals Insiders Sold Shares Worth Over $6.3M - TradingView
Amneal Pharmaceuticals (AMRX) legal chief Daly sells 216,613 shares in August trades - Stock Titan
Amneal Pharmaceuticals (AMRX) director reports 168,573-share transaction and updated holdings - Stock Titan
AMRX (AMRX) files notice to sell 50,000 common shares - Stock Titan
What Amneal Pharmaceuticals (AMRX)'s Higher Guidance and Complex Generics Pivot Means For Shareholders - Sahm
Amneal (AMRX) major holder gets 12.8M shares in $375M Kashiv purchase - Stock Titan
Amneal (AMRX): Tushar Patel discloses 61.3M-share, 17.6% ownership in 13D/A - Stock Titan
Amneal Pharmaceuticals (AMRX) investor Chirag Patel details 8.4% stake after Kashiv deal - Stock Titan
Amneal Pharmaceuticals (AMRX) ownership shifts with $375M Kashiv deal and new shares - Stock Titan
Amneal Pharmaceuticals (AMRX) Co-CEO gains 6.38M shares in Kashiv acquisition - Stock Titan
Amneal Pharmaceuticals (AMRX) director reports 283,632-share grant tied to Kashiv deal - Stock Titan
Amneal Pharmaceuticals (AMRX) Co-CEO linked entities receive 6.38M shares in Kashiv deal - Stock Titan
AMRX (AMRX) plans Rule 144 resale of 146,403 equity compensation shares - Stock Titan
Amneal Pharmaceuticals, Inc. SEC Filing (Aug 12, 2026) - Stock Titan
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine? - Yahoo Finance
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist? - Yahoo Finance
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now? - Yahoo Finance
Amneal Pharmaceuticals Inc (AMRX) Shares Fall 4.3% -- GF Value S - GuruFocus
Charles Schwab Corp (AMRX): holder files Form 144 for 2.92M-share sale - Stock Titan
Amneal closes $1.1B Kashiv Biosciences acquisition - NJBIZ
Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Amneal Pharma completes acquisition of Kashiv BioSciences - Pharmabiz.com
California State Teachers Retirement System Purchases 56,588 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals Adds $350 Million Incremental Term Loan to Fund Kashiv Acquisition - TradingView
Amneal completes acquisition of Kashiv BioSciences By Investing.com - Investing.com UK
Amneal acquires Kashiv BioSciences, creating global biosimilars leader - Telangana Today
Amneal completes acquisition of Kashiv BioSciences - Investing.com
Amneal Pharmaceuticals Completes Kashiv BioSciences Acquisition - Moomoo
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader - The Manila Times
Amneal's New Global Platform Spans Biosimilar Research to Commercialization - Stock Titan
Oliver Luxxe Assets LLC Has $1.46 Million Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Renaissance Technologies LLC Acquires 260,237 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Assenagon Asset Management S.A. Has $42.33 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality - webull.com
Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Segall Bryant & Hamill LLC Sells 113,969 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Evaluating a Robust 7.43% Potential Upside - DirectorsTalk Interviews
Amneal Reprices $2.08B Term Loan, Cuts Margin 50 Bps; Sees ~$12M Annual Interest Savings - TradingView
UBS raises Amneal Pharmaceuticals price target on biosimilar growth - Investing.com
UBS Adjusts Price Target on Amneal Pharmaceuticals to $25 From $23, Maintains Buy Rating - marketscreener.com
amneal pharmaceuticals, inc. Positive Earnings Pre-Announcements - RTTNews
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.96%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):